Phase 2 N=100 Evaluating Simvastatin's Potential Role in Therapy
Alzheimer Disease
Primary: Change in Cerebrospinal Fluid (CSF) Beta-amyloid-42 — -5.2; -3.1 ng/L — p=0.966
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=54 Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer
Male Breast Cancer · Stage IIIB Breast Cancer · Stage IIIC Breast Cancer
Primary: Recommended Phase II Dose as Assessed by NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (Phase I) — 300 mg
Phase 2 N=10 Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer
Prostate Cancer
Primary: Phase 1: Maximally Tolerated Dose (MTD) of Cabazitaxel in Combination With Abiraterone Acetate — 25 mg/m^2
Phase 2 N=23 Using Telemedicine to Improve Veteran Sleep Apnea Care
Sleep Apnea Syndromes
Primary: Treatment Adherence — 3.4; 3.6 hours/night
Phase 2 N=16 Inhaled NO as an Anti-inflammatory and Anti-reperfusion Agent in Infants and Children Undergoing Cardiopulmonary Bypass
Congenital Heart Disease
Primary: Serum Inflammatory Mediators Post CPB — 3.8; 3.4; 90.9; 78.3 ng/mL — p=>0.05
Phase 2 N=202 Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers
Meningococcal Disease
Primary: Number of Subjects With at Least One Severe Solicited Adverse Event (AE) After Receiving One Dose of Either MenACWY-CRM Vaccine or MenACWY-TT. — 4; 2 Number of Subjects
Phase 2 N=405 Development of Rational Ways of Medical and Non-medical Treatment Methods for Metabolic Syndrome
Metabolic Syndrome
Primary: Blood Glucose Level — 6.05; 6.43; 4.58; 14.5 mmole/L
Phase 2 N=58 The Effect of NK1R Antagonism on Alcohol Craving and PTSD Symptoms in Alcohol Dependent Patients With PTSD
Alcoholism · Alcohol Dependence · Posttraumatic Stress Disorder
Primary: Alcohol Craving in Response to the Stress Script — 11.9; 12.9 units on a scale
Phase 2 N=25 Human Fetal Liver Cell Transplantation in Chronic Liver Failure
Liver Cirrhosis
Primary: Patient Survival — 5; 6; 4; 10 participants — p=0.4340
Phase 2 N=26 Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
Recurrent Uterine Corpus Sarcoma · Uterine Corpus Leiomyosarcoma
Primary: Tumor Response — 0 percentage of participants
Phase 2 N=16 Autologous Cell Therapy for Female Stress Urinary Incontinence
Stress Urinary Incontinence
Primary: Number of Participants That Experienced Biopsy Procedure-related Adverse Events — 1 participants
Phase 2 N=293 American Ginseng Extract in Preventing Respiratory Infection and in Reducing Antibiotic Use in Patients With CLL
Leukemia
Primary: Acute Respiratory Infection (ARI) Days — 8.30; 6.78 days — p=0.295
Phase 2 N=64 FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
Primary: Progression Free Survival (PFS) Rate — 13.5 Months
Phase 2 N=769 Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder
Major Depressive Disorder
Primary: Change From the End of Phase A (Week 8 Visit) to the End of Phase B (Week 14 Visit) in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score. — -8.20; -7.02…
Phase 2 N=148 Vitamin D in Treating Patients With Prostate Cancer
Prostate Cancer
Primary: Pattern of Response of Serum 25(OH) D3 Levels — 11.34; 24.84; 18.87; 26.91 ng/mL — p=<.0001